Actively Recruiting
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)
Led by University of Washington ยท Updated on 2026-04-17
2000
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
U
University of Washington
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients who have ovarian or other solid cancers. The study aims to identify risk factors and possible genetic or environmental causes for developing these blood cancers. This observational study involves patients with a history of certain solid tumors or blood disorders related to cancer treatment. Participants in this study provide blood samples and complete surveys to help researchers understand the relationship between genetic markers and the development of blood cancers after cancer therapy. Medical records are also reviewed to gather comprehensive information. There are no treatments given as part of this study, and it focuses on observation and data collection. During the study, researchers will measure the presence and changes of specific genetic mutations in blood cells, especially the TP53 mutation, over up to five years. They will assess how these changes relate to the risk of developing therapy-related blood cancers. Participants' medical histories, blood tests, and survey responses will be monitored regularly to track these outcomes and better understand the progression from non-cancerous mutations to blood cancers.
CONDITIONS
Brief Title
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have or have had ovarian, peritoneal, or fallopian tube carcinoma with a life expectancy greater than 6 months and completed or plan to complete at least 5 cycles of platinum-based chemotherapy
- Or have or have had a solid tumor and either have at least 4 months of exposure to a PARP inhibitor or a diagnosis of a blood disorder such as clonal hematopoiesis, cytopenia of unknown significance, or therapy-related myeloid neoplasm
You will not qualify if you...
- Life expectancy less than 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants provide blood samples and complete surveys while their medical records are reviewed.
Visits scheduled as needed for sample collection and surveys
Trial Site Locations
Total: 1 location
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
S
Swisher Lab Research Coordinators
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here